Masimo (NASDAQ:MASI) Updates Q4 2025 Earnings Guidance

by · The Markets Daily

Masimo (NASDAQ:MASI – Get Free Report) updated its fourth quarter 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 1.540- for the period, compared to the consensus estimate of 1.440. The company issued revenue guidance of $411.0 million-$411.0 million, compared to the consensus revenue estimate of $407.1 million.

Masimo Stock Down 1.8%

Shares of NASDAQ:MASI traded down $2.46 on Monday, hitting $136.46. 20,235 shares of the company’s stock were exchanged, compared to its average volume of 563,616. The firm’s 50-day moving average is $140.07 and its 200 day moving average is $147.06. The company has a market capitalization of $7.33 billion, a PE ratio of -12.95, a P/E/G ratio of 1.42 and a beta of 1.26. Masimo has a 1-year low of $125.94 and a 1-year high of $194.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.92 and a current ratio of 2.84.

Masimo (NASDAQ:MASI – Get Free Report) last announced its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. The company had revenue of $617.00 million during the quarter. Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. Sell-side analysts predict that Masimo will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on MASI shares. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Bank of America began coverage on Masimo in a research note on Monday, November 17th. They set a “neutral” rating and a $162.00 price objective for the company. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Wells Fargo & Company reiterated an “overweight” rating and set a $190.00 price objective on shares of Masimo in a research report on Friday, December 5th. Finally, BTIG Research increased their target price on shares of Masimo from $198.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $189.40.

View Our Latest Analysis on MASI

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Masimo by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after purchasing an additional 66 shares in the last quarter. Orion Porfolio Solutions LLC grew its position in Masimo by 2.2% in the second quarter. Orion Porfolio Solutions LLC now owns 4,871 shares of the medical equipment provider’s stock valued at $819,000 after purchasing an additional 104 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Masimo by 12.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,516 shares of the medical equipment provider’s stock valued at $255,000 after buying an additional 166 shares during the last quarter. Thrivent Financial for Lutherans increased its position in shares of Masimo by 1.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 10,596 shares of the medical equipment provider’s stock worth $1,782,000 after purchasing an additional 177 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in Masimo during the third quarter worth $46,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

(Get Free Report)

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

Recommended Stories